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1  introDuction
Direct genetic testing, until recently, consisted of either an examination of whole 
stained chromosomes (cytogenetics) or a DNA test which characterises a specific 
DNA sequence (molecular genetics). The genotyping microarray is a new genetic 
testing method that can replicate, combine and enhance the capability of these two 
established genetic testing methodologies. 
The great potential of microarray technology is its ability to perform many genetic tests 
simultaneously on one genetic sample. The high throughput, high resolution testing is 
not only more efficient than performing many separate tests (and potentially more cost 
effective), it also allows changes (mutations) to be found that are currently not detected. 
In the context of mutation screening, rather than screening, for example, for the five 
most common mutations that cause a disorder in a population, a whole gene can be 
screened in one experiment, thereby allowing multiple and rare deleterious mutations 
to be found routinely. In the cytogenetic context, smaller chromosomal changes, which 
may still cause a large physical effect, can be detected more readily than at present.
Microarrays are miniature, systematic arrangements of molecules (probes) on a solid 
substrate. They are often called ‘chips’ for their superficial similarity to computer 
microchips. The molecules on a microarray comprise any one of a number of different 
biological materials, but are generally DNA-based for genetic studies. The DNA to be 
tested is extracted from blood or tissue samples and allowed to attach to the DNA 
probes on the array. When the test sample binds to the matching DNA probe ‘spot’ 
on the array, a signal (usually fluorescence) is detected by a scanner or array reader. 
The data must undergo statistical analysis before it can be used to make predictions 
for diagnosis or treatment. Currently, the result is usually confirmed using another 
method before being accepted as accurate.
Microarrays were first developed for use in cancer research. They were used to 
measure the expression levels of various types of RNA (the intermediate between 
DNA instructions and protein product). The amount of RNA produced tends to 
reflect the amount of protein produced by a cell or tissue, and can also give an 
indication of how many copies of a particular gene are active or present. Changes in 
expression or gene copy number may drive cancer development. Microarrays may be 
used for typing tumours to determine what might be the most effective method of 
treatment, if any, with fewer side effects. The focus of this section, however, will be on 
the use of microarrays in determining DNA sequence variation (genotyping).
Genotyping microarrays have many high throughput uses and more are being 
developed over time. Current uses include microorganism identification (including 
the SARS virus as a corona virus); detection of antibiotic resistance; testing for, and 
of, genetically modified organisms; finding new drug targets; and tissue typing for 
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blood transfusion. Within the field of pharmacogenetics, there is now a cytochrome 
P450 microarray ‘chip’ to indicate how quickly an individual’s liver might process 
various chemicals including pharmaceuticals (and this is now FDA approved). 
Microarrays comprise a new technology, which is proving to be very good for 
diagnostic genetic testing where there is a phenotype to explain. Their use is now 
moving towards genetic screening however, where there are more implications for 
clinicians and others wanting to use the technology. 
This chapter aims to explore some of the current, albeit new, uses of microarrays in 
human genetic testing and the potential uses of the technology in the short to medium 
term. This section sets the context for the following, more detailed, examination of 
prenatal testing using microarrays.
2  the Basis oF genetic Disease
For more detailed information on the molecular basis of human genetic disease, consult 
a general genetics text.
DNA is the substance that holds the genetic instructions for making proteins and other 
types of biological materials. DNA is condensed into structures called chromosomes. 
DNA is made up of four principal nucleotides: adenosine (A); cytodine (C); guanosine 
(G); and thymidine (T). C and G nucleotides and A and T nucleotides specifically 
pair up to form double-stranded DNA. DNA encodes not only the instructions for 
the specific protein sequence (coding DNA) but also the regulatory instructions for 
when, where and how much protein to make (non-coding DNA). Figure 1 illustrates 
how double-stranded DNA is compacted into chromosomes.
Figure 1: DNA to chromosomes
Source: Image modified from Qui, 2006.
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Genetic disorders and syndromes can be caused by as little as a change in one 
nucleotide of DNA or as much as the deletion or duplication of a whole chromosome. 
Microarrays can be used to screen for both chromosomal changes and molecular 
mutations. 
2.1  smaller molecular variations and the hapmap
A number of types of small molecular change (mutation) may result in a disorder. 
These range from a single change in a nucleotide, which may alter a crucial amino 
acid in a protein, through to variously sized small deletions and insertions, which 
may change the protein sequence or even introduce a premature ‘end-of-protein’ 
(stop) signal. The manner in which some of these changes may modify the function 
of a gene is illustrated in Table 1. 
normal allele the one Big Fly haD one reD eye.
missense thQ one Big Fly haD one reD eye.
nonsense the one Big.
Frameshift the one QBi gFl yha Don ere Dey e.
Deletion  the one Big haD one reD eye.
insertion the one Big wet Fly haD one reD eye.
inversion the one Big ylF haD one Big eye.
Duplication the one Big Fly Fly haD one reD eye.
expanding mutation
 generation 1 the one Big Fly haD one reD eye.
 generation 2 the one Big Fly Fly Fly haD one reD eye.
 generation  the one Big Fly Fly Fly Fly Fly haD one reD eye.
Table 1: Types of molecular mutations. These gene ‘sentence’ examples illustrate the 
effects of various types of molecular mutation on the meaning or function of the sentence 
(gene). The site of the mutation or the actual change is underlined
Source: Modified from Lewis, 2003
This variation in the genome may cause single-gene (monogenic) disorders, and this 
type of variation is often called a mutation. However, most of the variation in the 
genome causes no change to the function of the gene or consequent protein at all, 
and the effect may be neutral or even, occasionally, advantageous; variation that is 
not strongly linked to disease is often called polymorphism. 
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Single nucleotide polymorphisms (SNPs) are relatively common in the genome. They 
may occur anywhere in the genome and the majority are thought to be close to neutral 
in effect. Some SNPs, however, may be linked to increased risk of a particular disorder.
Smallish blocks of chromosomes have been shown to ‘travel together’ when they 
are passed down a family line over many, many generations. The polymorphisms 
that travel together are easier to determine in newer populations (such as from the 
Pacific Islands) than in older populations (such as from Africa), as there has been less 
time for the chromosomal blocks to break up. The more generations down which a 
chromosome block is passed, the more likely it is to be broken up. 
Included in these blocks of chromosomes is the normal variation (polymorphism) 
that you would expect to find in any genome. In order to characterise this variation 
quickly, the HapMap project has analysed more than four million single nucleotide 
polymorphisms in four population groups from Asia, Africa and Europe. They have 
been able to determine which polymorphisms tend to travel together. By looking at 
one polymorphism in a particular group (a tag), researchers can deduce which other 
polymorphisms are there with it. Using this information, a genome can quickly and 
economically be scanned to give good information about which other polymorphisms 
are present. Researchers are now trying to associate these polymorphic tags to 
complex conditions and traits.,
2.2  larger chromosomal variations
Changes in the number and structure of chromosomes are of most interest at the 
prenatal and childhood testing stages. These changes produce a state called aneuploidy, 
where there are extra or missing whole chromosomes. An extra or missing portion of 
a chromosome is known as a segmental aneuploidy.
Changes in the copy number of whole chromosomes commonly affect the viability 
of pregnancies. Most large deletions and duplications typically miscarry early in 
gestation. Some fetuses with specific types of aneuploidy can survive pregnancy but, 
even in these types, many will miscarry before term.
Duplication of whole chromosomes 13 (Patau syndrome), 18 (Edwards syndrome), 
21 (Down syndrome), X and Y (several syndromes including Klinefelter syndrome), 
are the most common aneuploidies found in newborns and children, although Patau 
and Edward syndrome are typically fatal within a few days to a few months of birth. 
The only viable whole-chromosome deletion is of the X sex chromosome (Turner’s 
syndrome).
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Segmental deletions or duplications (of parts) of chromosomes also cause various 
conditions or syndromes, e.g. Cri-du-chat and Williams syndrome. Children 
diagnosed with developmental delay are often found to have small chromosomal 
perturbations. Segmental aneuploidies are less likely to be lethal because fewer genes 
are affected.
Changes (up or down) in expression of multiple genes can have multiple physical 
effects. The wide-ranging effects of large and smaller changes to chromosomes 
are the result of relative changes in expression of hundreds or even thousands of 
genes. Many of these gene expression changes will have no effect; but, generally, the 
expression of enough essential genes is affected to cause many body systems to be 
affected also. 
Parts of chromosomes may also be moved around from their ‘home’ chromosome 
through a number of mechanisms, to produce a state known as translocation. 
Sometimes the translocation is a direct swap of genetic material between two 
chromosomes. This exchange is known as a reciprocal translocation. In other 
situations, the long arms of two chromosomes merge, as do the respective short arms, 
creating two new chromosomes (Robertsonian translocation). Some translocations 
cause disorders because two areas of the genome are abnormally brought together, 
destroying functional genes, changing the expression pattern of genes or creating 
new genes. They may also be harmless to the carrier (as the total complement of 
chromosomes has generally not changed). Translocations do cause fertility problems, 
however, because some of the eggs or sperm created in a carrier are chromosomally 
unbalanced, in turn creating embryos with segmental aneuploidies. 
The last main group of chromosomal rearrangements are inversions. An inversion is 
where a segment of DNA is swapped in orientation. This may be completely neutral 
(or even advantageous) or may cause some of the problems seen with translocations, 
such as the elimination of a functional gene, the change of the expression pattern of 
a gene or the creation of new genes. 
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Figure 2: Metaphase chromosome spread. Cells are grown in the laboratory, and then 
stopped at the metaphase stage of cell division, when the chromosomes are condensed 
and easily seen. Chromosomes are freed from the cells and stained with a dye to give the 
characteristic ‘banding’ pattern and to make them more visible. This karyogram shows 
a male karyotype, with one X and one Y chromosome.
Source: Image sourced from Leiden University Medical Center
what are chromosomes?
all genetic material (Dna) in the nucleus is wound up into structures called 
chromosomes. The Dna is coiled around on itself (like a twisted rubber band) 
and around a protein scaffold. This enables a large amount of Dna to be reduced 
in size so as to fit into a cell.
Humans typically have twenty-two chromosome pairs and two sex chromosomes 
(either an X and a y or two Xs): forty-six chromosomes in all.
The area where like chromosomes pair up during replication is known as the 
centromere. The centromere is characterised by repeated Dna sequences and 
may be found anywhere from the middle to one end of the chromosome. 
The two ends of each chromosome are known as the telomeres. They are also 
repetitive Dna sequences.
chromosome arms extend from the centromere to a telomere. The short arm 
of a chromosome is known as the p arm (an abbreviation of petite) and the long 
arm is known as the q arm.
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2.  uniparental disomy and imprinting
Uniparental disomy is the presence of two copies of one chromosome from only 
one parent. There is a number of mechanisms whereby this situation can occur, the 
most common thought to be loss of an extra chromosome from an embryo where 
there are three copies (trisomy). This situation may cause disease in two ways. If the 
chromosomes present have a recessive, disease-causing mutation then two copies of 
the mutation result in a disorder. The other way in which uniparental disomy causes 
disease is when it involves imprinted genes. 
Approximately fifty-three imprinted genes in forty-one ‘groups’ are known in humans. 
With imprinted genes, only one of the two copies of the gene is expressed, according 
to which parent it was inherited from. If the gene is only active on the paternally 
inherited chromosome, for example, then a loss of the paternal copy of the gene can 
result in a disorder. This is one of the mechanisms through which changes to genes 
close to SNRPN cause Prader-Willi syndrome. Deletions in or of the imprinted gene 
from the relevant parent are another common mechanism for imprinting disorders.
2.  copy number variation
Until recently, only very large and very small changes in the genome have been studied 
in detail. Researchers are now beginning to explore medium-size (submicroscopic) 
chromosomal differences (1 000 to 50 000 nucleotides) that turn out to be common 
variations within and between populations. These medium-size gains and losses of 
copy number are known as copy number variation (CNV). Recent studies show that 
CNV may affect up to 12 per cent of the whole genome, far more than previously 
anticipated. Any two humans, however, will only vary at a small number of the 
approximately 1500 chromosomal locations characterised so far.
Many CNVs are likely to be harmless, but some are linked to developmental delay 
and others to complex disorders such as Alzheimer’s and Parkinson’s disease.
The existence of this extensive variation both complicates and simplifies the use of 
genetic testing. On the one hand, we now know there is a large amount of CNV that 
is not linked to medical disorders. This knowledge does complicate interpretation of 
genetic testing results, as we cannot necessarily distinguish between neutral or disease-
causing variations. On the other hand, now that we know of its existence, we can and 
have begun to characterise the extent of the CNV and can record the variation, how 
commonly it is found and possible effects on phenotype in large databases. This in turn 
will improve interpretation of genetic testing results. Increased genetic testing of this 
type and reporting of results to these databases will also increase the body of knowledge 
around what may (or may not) cause or be associated with various conditions.
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  what are genotyPing microarrays?
.1  Principles of microarrays
Single-stranded DNA can bind to another single-stranded DNA molecule with 
complementary sequence, to form the double-stranded DNA helix. The method of 
binding or base pairing has been likened to a zip that can be joined or separated.
All DNA microarrays comprise a solid support with specific pieces of DNA (probe) 
attached to it in a regular and defined manner. When (single-stranded) test DNA 
is added to the array, the probe DNA on the array is chemically ‘attracted’ to the 
test DNA with the ‘opposite’ (complementary) sequence. Any two pieces of exactly 
complementary DNA ‘fasten’ together (hybridise) to form double-stranded DNA 
and can be detected through a variety of means. 
If the sequence doesn’t match exactly (particularly for short pieces of probe DNA), 
then there is no hybridisation and no signal to analyse. Both hybridisation and non-
hybridisation data give useful information about the test DNA being analysed. If 
the sequence, or the size of the DNA probe fragments, is altered, the arrays become 
adaptable for specific purposes. 
The solid support is generally a microscope slide-size piece of glass (approximately 
75 mm x 26 mm) although there are many commercial companies with proprietary 
designs now making their own microarrays for sale. DNA is ‘printed’ onto the glass 
in discrete microscopic spots of down to approximately one nanometre. The DNA 
probes are firmly attached to the solid support by one of a number of methods and 
are difficult to remove under experimental conditions. 
Short fragments of DNA (oligonucleotides) for arrays can be synthesised in the 
laboratory. Longer fragments of DNA must be prepared from existing pieces of 
cloned DNA. Oligonucleotides can also be build up, one nucleotide at a time, on to 
the solid support of the array. A variation on a glass slide support is miniature beads, 
onto which specific oligonucleotides are synthesised. The beads are then mixed with 
other beads sporting differing sequences and are poured onto a small tray support. 
The position of each type of bead, held on the tray by electrostatic forces, is defined 
before it leaves the factory.
Microarrays have a varying number of spots of DNA, depending on what they are 
being used for. Some microarray sets being commercially produced can contain up 
to 500 000 separate spots.
Each individual spot can contain DNA with a unique sequence. In practice, however, 
there is some redundancy (repetition) to serve as an internal check. If two or more 
spots with the same DNA probe sequence give similar results in an experiment or test, 
and are on different areas of an array, then one can be more confident of that result. 
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.2  oligo-based microarrays 
Oligonucleotide-based arrays are probably the most versatile type of array. Short 
oligonucleotides (approximately twenty-five nucleotides long) are synthesised in the 
laboratory and can be designed to hybridise to any DNA sequence of interest. They 
are sensitive enough to be able to detect one mismatch in twenty-five nucleotides.
Oligo-microarrays can be used in two principal ways. First, they can be used to scan 
a chromosome or genome; for example, by using known mutations as a design basis 
or using tag SNPs from the HapMap project. 
The second method is to ‘resequence’ a gene or small genomic area. This is done 
by preparing oligonucleotides that match every possible option at each nucleotide 
position. A large series of overlapping oligonucleotides is produced; each 
oligonucleotide sequence is shifted one nucleotide along from the last. For each 
nucleotide position in a genomic area of interest, all four alternatives (A, C, G or T) 
can be included in the microarray. This gives massive redundancy, as each nucleotide 
can be interrogated by up to two hundred different probes. They can also be used to 
detect an insertion or deletion of a nucleotide(s), if no genomic DNA binds to any of 
the four alternatives. This use may be suitable for mutation screening for monogenic 
disorders such as cystic fibrosis.
Figure 3: A resequencing microarray. A portion of the fluorescence pattern of the 
microarray (left) has been magnified on the right. Each column in the right hand picture 
represents four similar oligonucleotides, with a variation at just one nucleotide position. 
The top row has the A nucleotide alternative in that position; the second row, the C 
nucleotide; the third row, the G; and the last row, the T. Using this information, DNA 
sequence can be read off the microarray from the position of the fluorescent spot
Source: Maitra et al., 2004
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.  array cgh (acgh)
This technique is described more fully in the chapter by Mildred Cho, ‘Array Comparative 
Genomic Hybridisation (aCGH): An Analysis of the Current Technology and its Future 
in Prenatal Diagnosis’. 
Comparative genomic hybridisation (CGH) is sometimes used in diagnostics and 
prenatal sample screening. In this technique, the test (e.g. prenatal) and control 
(‘normal’) DNA samples are separately labelled with different-coloured fluorescent 
dyes, then combined in equal quantities. The combined DNA is hybridised to a 
traditional chromosome spread and gain or loss of DNA copy number is shown by 
differences in the relative fluorescence of each dye. 
The modified microarray version involves hybridisation of the combined DNA to 
a microarray. Instead of hybridising to a chromosome spread, the test and control 
DNA are hybridised to smaller pieces of human DNA. Many of these human DNA 
clones are bacterial artificial chromosomes (BACs), as they are replicated in bacteria 
to make many copies for use on the microarrays; but there are also other types of 
clone system used. 
In prenatal testing, the choice of BAC DNA spotted onto the microarray is currently 
focused on those areas that are known to be more commonly affected by aneuploidy 
(unbalanced number of chromosomes) or to cause specific disorders. The majority 
of these involve deletions. The combined test and normal DNA will hybridise to 
BACs that share the same (or similar) DNA sequence. If there is a large deletion in 
the test DNA, then it will not bind to the BAC that is equivalent to the missing 
DNA. The normal sample should hybridise, however, resulting in a difference in 
fluorescence for that spot. If there is a duplication, the test signal will be greater than 
the ‘normal’ signal.
The use of larger pieces of DNA means that this type of testing is directed at large 
deletions. Smaller deletions or duplications (less than 80 000 nucleotides) will not 
be detected.
The newest Baylor College of Medicine prenatal microarray has 1475 different clones, 
although many overlap to ensure test integrity. In addition to looking for specific 
chromosomal disorders, the centromeres and telomeres are closely covered, as 
loss or gain of material in these regions can cause developmental delay and other 
clinical effects.
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  recent anD Future uses oF microarrays
It is difficult to predict how microarrays might be used in the future. Some current 
and up-and-coming uses are discussed in this section.
.1  Prenatal screening
This technique is described more fully in the chapter by Mildred Cho, ‘Array Comparative 
Genomic Hybridisation (aCGH): An Analysis of the Current Technology and its Future 
in Prenatal Diagnosis’.
There are two current methods for obtaining prenatal tissue for genetic testing. 
Amniocentesis is by far the most common; amniotic fluid samples are taken between 
fifteen and twenty weeks of gestation. Chorionic villus sampling is performed earlier 
than this (ten to twelve weeks of gestation) and involves taking a small sample of part 
of the placenta.
The difference in timing between the two sampling techniques suggests that different 
arrays could be used. As chorionic villus samples are from earlier in pregnancy, they 
may still carry major perturbations that will cause a miscarriage later in the pregnancy 
but before amniocentesis sampling. Having said this, the major chromosomal 
perturbations that could cause this outcome are likely to be detected by current 
microarrays anyway.
Due to the novelty of aCGH as a screening method, fetal samples are karyotyped 
in the traditional manner, as a backup test and potentially for confirmation of any 
abnormalities found. Fluorescent in situ hybridisation (FISH) is another technique 
used to confirm abnormal results.
The presence of copy number variation (CNV) in the genome means that all 
‘abnormalities’ are then looked for in parental blood samples. If the change is found 
in an apparently functional adult, then the CNV is reported as a neutral variant, 
unless there are other suspicious circumstances.
Many microarrays used for screening are generated ‘in-house’ and are known as 
‘home-brew’ arrays, particularly those used for array CGH (aCGH).
Non-invasive sampling of fetal cells or DNA in the maternal blood stream is still in 
its infancy. If the fetal cells or genetic material can eventually be isolated reliably from 
maternal material, then microarrays may play a significant role in prenatal screening.
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.2  Preimplantation genetic diagnosis (PgD)
Microarrays offer more comprehensive screening, of aneuploid embryos in particular, 
than current technologies. The increased sensitivity from using microarrays means 
that many more aneuploidies can be detected, hopefully leading to improved rates of 
implantation and successful pregnancy. The current limit on how many chromosomes 
can be screened in preimplantation genetic diagnosis (PGD) (approximately 
eleven chromosomes at best) is postulated as the reason why aneuploidy screening 
(preimplantation genetic screening) is less successful than it intuitively ought to be. 
Current techniques only detect the presence or absence of a small part of any one 
chromosome so segmental aneuploidies are generally not detected either.
Use of microarrays in PGD has been published in a small number of papers, but 
they are research papers only. Routine implementation of this technique is dependent 
on a reliable method of whole genome amplification (WGA, see following information 
box). 
Aside from WGA, the other impediment to successful implementation of microarray 
screening of embryos is mosaicism. Many embryos apparently have some cells with 
a normal chromosomal complement and some that are aneuploid. Which cell, in the 
eight-cell embryo, is biopsied is a matter of chance and can lead to a situation where 
some ‘mostly normal’ embryos are discarded as being aneuploid and vice versa. There 
is also recent evidence that some mosaic embryos can ‘correct’ themselves and at a 
later embryonic stage be effectively chromosomally ‘normal’. Whilst this issue does 
not prevent successful PGD, it reduces the chances of success by reducing the number 
of healthy embryos for transfer.
whole genome amPliFication (wga)
in PGD, there is only a very small amount of genetic material to analyse: that 
which can be freed from a single cell. To have any chance of genetic analysis (using 
current technology), the Dna from the single cells must be copied many times 
over. For the technique to be useful in microarray analysis, the whole genome 
must be copied evenly so that there is the same amount of Dna, proportionally, 
that there was in the original cell. if, for some technical reason, a part of the 
genome is copied more frequently (or less frequently) than the rest of the 
genome, then the microarray result may show aneuploidy where there is none. 
whilst techniques for copying Dna are improving, there are significant problems 
in reliable amplification giving accurate results. current wGa techniques merely 
exacerbate the problems that exist in amplifying a small section of Dna for 
genetic testing.
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.  newborn screening
DNA screening and profiling of newborns is discussed in more detail in the chapter 
‘Newborn screening: Present and future’.
The use of microarrays has been suggested for the screening of newborns for early 
onset disorders. Current technologies use indirect measurements for genetic disorders, 
such as metabolic molecules from a blood sample. Metabolic newborn screening (as 
it is known) is effective in detecting early onset disorders as the disorders manifest 
within two or three days of birth. There is now some discussion around extending 
screening to include direct DNA screening. 
Genetic technologies such as microarrays would be useful as the testing can be 
targeted to specific early disorders. However, when compared to metabolic screening 
in which there is an actual medical condition manifesting itself, there remains much 
uncertainty in interpretation and use of these results. Some disorders have a variable 
manifestation, even when two individuals carry the same causative mutations. 
Some mutations are so rare that the possible effects are unknown, with respect to 
medical symptoms. With other disorders, not all genetic causes are known and some 
newborns may miss out on crucial early treatment.
Genetic profiling of newborns is a possibility in the future; although in one recent 
study it was dismissed due to cost and technological barriers. There are also many 
ethical and policy issues that need to be addressed before this use of microarrays is 
implemented.
.  childhood and adult testing
The subject of genetic testing of children is comprehensively covered in the report by 
Deborah Lawson.
Apart from the potential for newborn screening or profiling, the current use of 
microarrays in children is for diagnostics. 
Microarray testing is very efficient, as many tests can be performed simultaneously; 
but all the issues associated with genetic testing in children are amplified by this 
efficiency. Unless the child has symptoms that are consistent with loss or gain of 
genetic material (i.e. aneuploidy), the question then becomes, ‘Which tests do we 
perform on this sample?’ The answer usually depends on the symptoms exhibited; 
but, for commercial efficiency, most microarrays would include many more genes and 
mutations than are needed for a specific child. Thus, considerably more information 
is obtained than is needed. Production of a wide variety of customised microarrays 
is not yet viable. 
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The oligonucleotide-based resequencing microarrays have a great deal of potential 
for carrier screening and susceptibility screening in adults. 
In the United States, there is a national programme offering parents-to-be screening 
for carrier status for common cystic fibrosis (CF) mutations. If both parents are found 
to be carriers of a CF mutation, prenatal testing of the fetus (or embryos) can then be 
offered. Only twenty-three of the ~1500 described mutations are used for screening. 
This selective screening leaves a small risk that both parents may still be carriers yet 
one or both may get a negative result. If all known mutations can be put on a single 
microarray, then this risk is negligible. On the other hand, there have already been 
documented issues with clinicians or parents misunderstanding the implications of 
results from the current small screening panel. Again, the issues of interpretation and 
understanding could be magnified with an expanded screening panel.
For disorders such as heritable breast cancer, some laboratories sequence the entire 
BRCA 1 and 2 genes. Other laboratories screen only for common mutations associated 
with this condition, at least initially. A great deal of time could be saved if these 
two genes could be resequenced on a microarray, in their entirety; rare mutations 
could then easily be detected, rather than requiring the use of a two or three tier 
screening process.
The field of pharmacogenetics is already putting microarrays to use. There is an 
FDA-approved microarray that screens the cytochrome p450 gene, to deduce how 
substances, including pharmaceuticals, are processed in the liver. Drug dosages can 
be altered according to whether someone is a ‘fast’ or ‘slow’ processor of drugs such 
as chemotherapies or warfarin. A comprehensive blood-typing microarray is also in 
development for frequent users of blood transfusions. The more closely matched a 
blood transfusion, the better the result and the less likely a person is to develop an 
immune response to donor blood.
Expression profiles have been used to differentiate and categorise apparently similar 
cancer subtypes, by comparing those who respond to a specific treatment and those 
who have a poor long-term prognosis, ‘apparently reflecting the variation in tumour 
proliferation rate, host response and differentiation state of the tumour’. Detected 
changes in expression levels (up or down) have been used to find molecular markers 
for response to therapeutic treatments (before and after treatment), which can then 
be used in developing treatments.
In the future, genotyping microarrays could be designed to assess genetic risk of 
complex disease, such as heart disease, diabetes, Alzheimer disease and other late 
onset disorders. The microarrays could only assess the genetic risk, however, and 
complex disorders have significant environmental influences.
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.  limitations
Despite the many positive possibilities regarding microarrays in clinical genetics, 
there remain some negatives, although not all are unique. Some are mentioned later 
in this chapter; others, such as interpretation of ambiguous results, are covered in the 
chapter by Mildred Cho, ‘Array Comparative Genomic Hybridisation (aCGH): An 
Analysis of the Current Technology and its Future in Prenatal Diagnosis’.
Despite the glib descriptions of how the technology works, microarrays remain a 
technically demanding technique. There are issues of reproducibility as well as 
interpretation of results. This is discussed more fully in the next section.
The technology is currently expensive, microarrays costing approximately NZ$1000 
per chip. Labour, materials for processing samples and, in particular, the machinery 
needed to complete the entire process involve additional cost.
Current limits placed on genetic testing, in the form of licensing of patented 
information, are also a problem with microarray testing. Obtaining permission 
to licence an individual gene test and/or prohibitively expensive licensing fees are 
currently affecting diagnostic uses of microarrays.
Microarrays cannot detect changes in the entire set of chromosomes (whole ploidy). 
If, for example, there are three copies of each chromosome in a prenatal sample, then 
the relative amount of DNA will be the same and will be reported as ‘normal’. The 
limits of the sensitivity of microarrays are also being explored in respect of mosaicism. 
Mosaicism refers to the situation in which some parts of the body contain one set 
of genetic information and cells in other parts of the body contain another set, the 
result of a late mutation event. In the example of the trisomy 21 (Down syndrome) 
mosaicism, some cells will have three copies of chromosome 21 and some cells will 
have two copies. Depending on when and where the mutation event occurs (e.g. 
the loss of an extra chromosome 21), the tissues affected will vary from person to 
person and those with mosaicism will have different levels of ability. Microarrrays 
are thought to be able to detect as little as 30 per cent or less mosaicism in a tissue 
sample. This does not mean that mosaicism will be detected, however, as it depends 
which tissue is examined for the changes.’’’
1
  the new ZealanD situation
In New Zealand, microarrays are currently used only in research laboratories. Some of 
this research usage is in the context of screening for targets for clinical applications or 
trials, an excellent example being finding clinically relevant targets for cancer profiling.
Clinical services are certainly not using microarrays in genotyping or any other 
application as yet; although some laboratories have apparently been investigating use 
of aCGH for diagnostic applications. The fact that only one laboratory in the United 
States is commercially offering aCGH for prenatal screening suggests that this use is 
some way off in New Zealand.
.1 molecular genetic testing in new Zealand, 200
The 2003 report has also been reviewed by Deborah Lawson in the section of her report 
entitled, ‘Genetic Testing of Competent Minors’.
There is no apparent systemic overview of genetic testing in New Zealand and the 
introduction of new testing technologies appears to be ad hoc. There have been a 
number of reports since 1995 on the subject in the New Zealand context but there 
appears to have been no progress concerning implementation.
Genetic services in New Zealand are divided into the Northern (upper North Island) 
and Central and Southern (the rest of New Zealand) Regional Genetic Services. These 
groups are separately funded and have nominal support and supervision by ‘host’ 
District Health Boards (DHBs), Auckland and Capital Coast DHBs respectively. There 
are four principal cytogenetics laboratories (in Auckland, Hamilton, Wellington and 
Christchurch) and two main molecular laboratories (Auckland and Christchurch, 
with limited services in Wellington) offering genetic testing services, also under the 
aegis of local DHBs. Most testing is referred through genetic services, with some 
referred through various specialities (including obstetrics and paediatrics) and a 
limited amount through primary health services such as general practitioners.
The 2003 report reviews the current molecular genetic testing situation in New 
Zealand and finds it wanting. It points to a lack of criteria for assessment of clinical 
validity and utility of tests; a lack of testing capacity due to funding and personnel 
shortages; and a lack of coherence in and possible duplication of services offered 
by laboratories. It also makes suggestions with regard to consent, use of different 
testing methodologies, appropriateness of testing and the need for education of both 
medical professionals and the public.
Since then, there has been little overt progress; although it seems that DHB New 
Zealand (which co-ordinates the individual regional DHBs) ‘has now set up an expert 
group to prepare for the improvement to genetic services’.
2
  conclusions
The use of microarrays is still predominantly in the research sector. There has been 
some movement into the clinical testing and diagnostics arena internationally, but 
the eventual utility in clinical screening remains to be seen. The diagnostic aspect of 
microarrays has been enthusiastically reported in the clinical and scientific literature 
and remains one of the most likely uses of the technology as the cost comes down.
There is still a technology block for use of microarrays with preimplantation genetic 
diagnosis (PGD) for aneuploidy screening in the form of whole genome amplification. 
If this problem can be overcome, microarrays could foreseeably make a positive 
difference to implantation rates and reduce miscarriage rates for those who choose 
to use PGD for this purpose. PGD requires, however, that IVF be used to generate 
embryos for testing. It is therefore unlikely that it will ever be used outside fertility 
clinics and, even then, only for a subset of clients. Future use remains debatable. 
As cost comes down, microarrray technologies will likely supersede the existing 
cytogenetic technologies as a first-line prenatal test. Arrays are faster and potentially 
offer more detailed screening for disorder-causing chromosomal changes. This 
does not preclude simultaneous karyotyping as a method for confirming any larger 
abnormalities, or use of other techniques for later confirmation of an abnormal result. 
All cytogenetic results should be confirmed, preferably by using another method. As 
knowledge increases regarding the effects of medium to large chromosomal changes, 
(ironically) through increased testing as well as new research data, uncertainty about 
the seriousness of particular changes will be reduced.
There is, however, still the difficulty of explaining the technology and results to a lay 
audience, and a number of other ethical issues have been raised around the use of 
microarrays for prenatal screening. In addition, microarray use in prenatal screening 
currently requires an invasive procedure to obtain fetal material for testing. Again, 
unless there are developments in non-invasive testing, this technology will be limited 
to those women already undergoing amniocentesis or chorionic villus sampling.
A debate exists regarding how much genetic information is useful and the advantages 
and disadvantages of selective versus whole genome screening. There is a corollary 
with the use of whole-body CAT and MRI scans for simple health ‘check ups’. 
Abnormalities may be detected that have no effect on the quality of life; but, because 
they have been found, they are investigated or treated unnecessarily. The more 
targeted the microarrays to specific clinical questions, the less likely this is to occur.
Genetic services in New Zealand are currently stretched. Introduction of routine use 
of microarrays would require a substantial investment, not only in technology and 
laboratory staffing, but also in clinical genetics and counselling personnel.

Implementation of new testing technologies in New Zealand currently appears to 
be driven by the clinical testing laboratories, on a cost recovery basis. There appears 
to be no national strategy for monitoring and introducing new techniques and 
technologies. Whilst this is not necessarily a negative, it may preclude a national push 
for the introduction of new genetic testing tools; particularly if this were to be based 
in a single laboratory, in competition with others. In addition, private genetic testing 
services have not been established in New Zealand or Australia. This may or may not 
affect whether laboratories offer new services. The promised follow-up to the 2003 
report on molecular genetic testing in New Zealand is apparently being carried out 
by DHBNZ. We await their report with some anticipation.
Beyond microarray technologies, rapid whole genome sequencing is being touted as 
the next revolution in genetic testing. It is likely that rapid whole genome sequencing 
will become viable in the medium to long-term future. This technology reveals 
the ultimate genetic information: the exact sequence of the genomic DNA. This 
information is superior to the limited data from microarrays, although it is likely 
to need more interpretation. It is unlikely, however, to detect ploidy changes, such 
as trisomies, without additional analysis. Detection of chromosomal copy number 
variation (CNV) is the principal driver of most current and future PGD, prenatal 
and diagnostic testing.
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